But has the correct dose been chosen for phase 3 trials of this agent, which is one of several possible replacements for warfarin in development? (Agnelli G et al. <i>Circulation</i>; published ...

However, compared with aspirin, rivaroxaban was associated with higher rates of major bleeding (risk difference, 0.9 percentage points; 95% CI, –0.1 to 3.7) and intracranial hemorrhage (risk ...

In the fall of 2018, the 2.5-mg dose of the name-brand rivaroxaban was introduced to the U.S., when it was approved for prevention of major adverse cardiovascular events in CAD and PAD.

A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose aspirin revealed a link between rivaroxaban and higher rates of major bleeding and ...